Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 MAD study of NP10679 in healthy adults
NCT04007263Phase 1Completed
- Sponsor
- NeurOp, Inc.
- Start
- Apr 2019
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NP10679 in ischemic stroke, subarachnoid hemorrhage (SAH), postoperative pain and 2 more (4 arms), sponsored by NeurOp, Inc. Primary endpoints: Incidence of adverse events as a measure of safety and tolerability at 10 days and Plasma concentration of parent drug at 9 days. Started Apr 2019; status: completed.
02
Drugs
NP10679
03
Conditions
ischemic strokesubarachnoid hemorrhage (SAH)postoperative paintreatment-resistant depression (TRD)substance use disorder (SUD)
Beyond the preview
Go deeper on NCT04007263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04007263.